Prenatal exposure to ADHD medications, mostly methylphenidate, was not associated with an increased risk of neurodevelopmental disorders or growth restriction in exposed children.
There is evidence that screening for perinatal mood and anxiety disorders may improve outcomes; however, success depends on adequate resources for screening, diagnosis, treatment and follow-up.
 Some good news from our colleagues at the Maternal Mental Health Leadership Alliance (MMHLA)... The United States Department of Health and Human Services (HHS) is planning to launch significant initiatives addressing the maternal mental [...]
Every week we review the most recent publications in women’s mental health.
More infants who were exposed to strong agonists and opioids with long half-lives, including methadone, developed neonatal opioid withdrawal syndrome.
Postpartum women taking a drospirenone-only contraceptive pill experienced a decrease in depressive symptoms.
Intravenous ketamine or esketamine given at the time of cesarean delivery reduced risk for postpartum depression; predictive models are needed to determine which women are most likely to benefit from this intervention.
Every week we review the most recent publications in women’s mental health.
Every week we review the most recent publications in women’s mental health.
Symptom-onset dosing with a serotonin reuptake inhibitor for PMDD may have a greater impact on anger/irritability and relationship functioning than other symptoms.
